EICHORPublic-registry site landscape for NCT06568094, “A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer”, a Prostate Cancer study sponsored by Jiangsu HengRui Medicine Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06568094 (registry record) |
| Study title | A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer |
| Official title | An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Condition(s) | Prostate Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 2 |
| Site countries | China |
Patient-friendly overview of this study: eichor.com/study/NCT06568094.
Eichor generates a preliminary site-risk snapshot for NCT06568094 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
